Pharma 2020: Marketing the future Which path will you take?

April 4, 2019

The social, demographic and economic context in which the pharmaceutical industry (Pharma) operates is changing dramatically, as we noted in “Pharma 2020: The vision”, the White Paper PricewaterhouseCoopers* published in June 2007 (see sidebar, Seven major trends reshaping the pharmaceutical marketplace).1 All these challenges have major ramifications for the way in which Pharma markets and sells the medicines it develops – the subject on which we shall focus here. The industry has traditionally relied on aggressive marketing to promote its products. One recent study estimates that, between 1996 and 2005, total real spending on pharmaceutical promotions rose from US$11.4 billion to US$29.9 billion in the US (the only country for which expenditure on all major marketing and sales activities is available).2 Another study suggests that the true figure (including meetings and e-promotions) is closer to US$57.5 billion in real terms.

Spotlight

Hospital Samaritano

With 119 years of activity, the Samaritan is one of the country's leading centers of excellence in health. It has a Nucleus of Specialties with a focus on Cardiology, Gastroenterology, Neurology, Orthopedics, Oncology, Urology / Nephrology and Fetal / Perinatal Medicine. In addition, it has a complete and modern Service of Diagnostic and Therapeutic Medicine and Emergency area.

OTHER WHITEPAPERS
news image

Defragmenting Data for the Future of Pharma R&D

whitePaper | November 7, 2019

This in-depth paper will show you how to become data agile – tackling both technological issues and solutions, and the cultural and strategic framework needed around this to ensure success.

Read More
news image

Benefits of Semantic Enrichment Across the Drug Development Pipeline

whitePaper | January 24, 2022

Semantics is the process of assigning meaning to words and is a vital step in making unstructured scientific content machine readable, contextualizing otherwise unstructured information. It unlocks a host of benefits to search and analytics which are outlined below in the context of use cases relevant to drug discovery.

Read More
news image

MOLECULAR GLUES LANDSCAPE IN DRUG DISCOVERY

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

Read More
news image

Empowering MSLs to be the kings of Pharma’s New Frontier

whitePaper | December 12, 2022

To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy

Read More
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More
news image

Access to medicinal products

whitePaper | January 3, 2022

There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs

Read More

Spotlight

Hospital Samaritano

With 119 years of activity, the Samaritan is one of the country's leading centers of excellence in health. It has a Nucleus of Specialties with a focus on Cardiology, Gastroenterology, Neurology, Orthopedics, Oncology, Urology / Nephrology and Fetal / Perinatal Medicine. In addition, it has a complete and modern Service of Diagnostic and Therapeutic Medicine and Emergency area.

Events